Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Association of bone mineral density with a first-degree family history of diabetes in normoglycemic postmenopausal women

Yang, Lijuan MD; Hu, Xiang MD, PhD; Zhang, Hailing MD; Pan, Wei MD; Yu, Weihui MD, PhD; Gu, Xuejiang MD, PhD

doi: 10.1097/GME.0000000000001396
Original Articles
Buy

Objective: A first-degree family history of diabetes (FHD) contributes to increased risks of metabolic and cardiovascular diseases. Bone is an insulin-resistant site and an organ susceptible to microvascular complications. The goal of the present study was to investigate the association of FHD with bone mineral density (BMD) in postmenopausal women.

Methods: In all, 892 normoglycemic postmenopausal women were divided into subgroups of participants with or without a first-degree FHD. BMD was measured using dual-energy x-ray absorptiometry. Fasting plasma insulin and glucose levels were measured, and insulin resistance was evaluated using the Homeostasis Model Assessment—Insulin Resistance (HOMA-IR) index.

Results: The BMD of the lumbar spine and femoral neck were much higher in the participants with a first-degree FHD than in those without an FHD (all P < 0.05). Lumbar spine BMD and femoral neck BMD were both positively associated with HOMA-IR (P = 0.041 and P = 0.005, respectively). Multiple stepwise regression analysis showed that a first-degree FHD was an independent factor that was positively associated with lumbar spine BMD (standardized β = 0.111, P = 0.001) and femoral neck BMD (standardized β = 0.078, P = 0.021). A first-degree FHD was associated with increased BMD, insulin resistance, and hyperinsulinemia.

Conclusions: Our study indicated that normoglycemic postmenopausal women with a first-degree FHD exhibit increased BMD with insulin resistance and hyperinsulinemia. A first-degree FHD was an independent factor associated with elevated BMD in Chinese women after menopause.

Department of Endocrine and Metabolic Diseases, the First Affiliated Hospital of Wenzhou Medical University, Ouhai District, Wenzhou, Zhejiang Province, China.

Address correspondence to: Xuejiang Gu, MD, PhD, Department of Endocrine and Metabolic Diseases, the First Affiliated Hospital of Wenzhou Medical University, Ouhai District, Wenzhou 325000, Zhejiang Province, China. E-mail: guxuejiang@wmu.edu.cn

Received 18 March, 2019

Revised 16 May, 2019

Accepted 16 May, 2019

L.Y. and X.H. contributed equally to this work.

Funding/support: National key R&D Program of China (2016YFC1305202); Wenzhou Science & Technology Bureau (Y20170047).

Financial disclosure/conflicts of interest: None reported.

Online date: August 20, 2019

© 2019 by The North American Menopause Society.